Eli Lilly and Co Q1 2023 Earnings Call Summary - Thomson StreetEvents

Eli Lilly and Co Q1 2023 Earnings Call Summary

Eli Lilly and Co Q1 2023 Earnings Call Summary - Thomson StreetEvents
Eli Lilly and Co Q1 2023 Earnings Call Summary
Published Apr 27, 2023
22 pages (13470 words) — Published Apr 27, 2023
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Brief of LLY.N earnings conference call or presentation 27-Apr-23 2:00pm GMT

  
Brief Excerpt:

...A. Overview: Off to a strong start in 2023 with volume-driven revenue growth led by: 1. Incretin portfolio. a. b. Verzenio. c. Jardiance. 2. At 1Q earnings last year, Co. shared exciting data from SURMOUNT-1, first of Co.'s tirzepatide obesity Phase III trials. Today, excited to share the positive topline results for the SURMOUNT-2 Phase III trial for tirzepatide, which examine the safety and efficacy of tirzepatide in chronic weight management in a type 2 diabetes population. a. b. SURMOUNT-1 set a new bar for weight loss possible from a pharmacologic agent in non-type 2 diabetes population with obesity or overweight in a Phase III trial. i. SURMOUNT-2 does the same in the type 2 diabetes population. 3. Actions Announced on March 1 to Improve Insulin Affordability in US. a. Has led these efforts to make it easier for people to access LLY insulin, including through the broad implementation of $35 out-of-pocket cap and a significant reduction in list price for most of most commonly used...

  
Report Type:

Brief

Source:
Thomson StreetEvents
Company:
Eli Lilly and Co
Ticker
LLY.N
Time
2:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : Congrats on the quarter and the SURMOUNT-2 data. So on Mounjaro, I think it's comforting to see handsomely step-up from 4Q. I was wondering, can you help us think about the sort of continued cadence of improvement over the balance of the year? And then more importantly, how should we think about gross to net post approval in obesity? Is it reasonable to expect another kind of step down temporarily? Or would that not be the case? And then just on the Mounjaro and obesity, can you just walk us through the anticipated timelines here and the potential use of a priority review voucher?

Question: Kerry Ann Holford - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : Two questions, please. As you have mirikizumab. Can you provide any more detail on the specific issue the FDA has in manufacturing that when you expect to refile whether you would anticipate a Class 1 or 2 respondance and indeed whether you do expect to launch in the U.S. this year. Secondly, a question for Anat on prioritization. So, you've announced 2 divestments here in quick succession. Just interested to see, is there anything specifically driving this? Are there any additional noncore assets that you're seeking to monetize? And then as you divest these assets, what are your priorities for the use of cash? Clearly expecting to say internal R&D investments. But I'm wondering, too, if we can expect any more external R&D investment. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. APRIL 27, 2023 / 2:00PM, LLY.N - Q1 2023 Eli Lilly and Co Earnings Call

Table Of Contents

Eli Lilly and Co to Provide Alzheimer's Disease Update Summary – 2023-07-17 – US$ 54.00 – Edited Brief of LLY.N conference call or presentation 17-Jul-23 5:30pm GMT

Eli Lilly and Co at Goldman Sachs Healthcare Conference Summary – 2023-06-12 – US$ 54.00 – Edited Brief of LLY.N presentation 12-Jun-23 8:20pm GMT

Eli Lilly and Co at Goldman Sachs Healthcare Conference Transcript – 2023-06-12 – US$ 54.00 – Edited Transcript of LLY.N presentation 12-Jun-23 8:20pm GMT

Eli Lilly and Co at Bank of America Global Healthcare Conference Transcript – 2023-05-10 – US$ 54.00 – Edited Transcript of LLY.N presentation 10-May-23 5:00pm GMT

Eli Lilly and Co Q1 2023 Earnings Call Transcript – 2023-04-27 – US$ 54.00 – Edited Transcript of LLY.N earnings conference call or presentation 27-Apr-23 2:00pm GMT

Eli Lilly and Co at Cowen Health Care Conference Transcript – 2023-03-06 – US$ 54.00 – Edited Transcript of LLY.N presentation 6-Mar-23 6:30pm GMT

Eli Lilly and Co at SVB Securities Global Biopharma Conference (Virtual) Transcript – 2023-02-16 – US$ 54.00 – Edited Transcript of LLY.N presentation 16-Feb-23 5:00pm GMT

Eli Lilly and Co at Guggenheim Healthcare Talks Oncology Day Transcript – 2023-02-09 – US$ 54.00 – Edited Transcript of LLY.N presentation 9-Feb-23 3:10pm GMT

Eli Lilly and Co Q4 2022 Earnings Call Summary – 2023-02-02 – US$ 54.00 – Edited Brief of LLY.N earnings conference call or presentation 2-Feb-23 3:00pm GMT

Eli Lilly and Co Q4 2022 Earnings Call Transcript – 2023-02-02 – US$ 54.00 – Edited Transcript of LLY.N earnings conference call or presentation 2-Feb-23 3:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Eli Lilly and Co Q1 2023 Earnings Call Summary" Apr 27, 2023. Alacra Store. May 13, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q1-2023-Eli-Lilly-and-Co-Earnings-Call-B15413523>
  
APA:
Thomson StreetEvents. (2023). Eli Lilly and Co Q1 2023 Earnings Call Summary Apr 27, 2023. New York, NY: Alacra Store. Retrieved May 13, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q1-2023-Eli-Lilly-and-Co-Earnings-Call-B15413523>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.